Conference Correspondent

Conference Correspondent, ASH 2016 - Multiple Myeloma

Treatment with a Novel HDAC6 Inhibitor plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Conference Correspondent, ASH 2016 - Multiple Myeloma

Sustained Overall Survival in Patients with Smoldering Myeloma Receiving Lenalidomide-Based Therapy

Conference Correspondent, ASH 2016 - Multiple Myeloma

Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages

Conference Correspondent, ASH 2016 - Multiple Myeloma

Health-Related Quality of Life of Patients with Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance: Data from the Connect MM Disease Registry

Conference Correspondent, ASH 2016 - Multiple Myeloma

Ixazomib, Pomalidomide, and Dexamethasone Triplet Therapy in Patients with Double/Triple Refractory Myeloma

Conference Correspondent, ASH 2016 - Multiple Myeloma

Evaluation of Minimal Residual Disease in Relapsed/Refractory Multiple Myeloma Patients Treated with a Daratumumab-Based Regimen

Conference Correspondent, ASH 2016 - Multiple Myeloma

PREAMBLE: Real-World Efficacy Analyses in Multiple Myeloma Patients with One Line of Prior Therapy

Conference Correspondent, ASH 2016 - Multiple Myeloma

Retreatment with Daratumumab and Pomalidomide Among Refractory Patients with Multiple Myeloma

Conference Correspondent, ASH 2016 - Multiple Myeloma

Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma

Conference Correspondent, ASH 2016 - Multiple Myeloma

A New Risk Stratification Tool to Estimate Survival in Patients with Multiple Myeloma After First Relapse

1
2
3
4
5
6
7

Page 4 of 8
Results 31 - 40 of 80

SUBSCRIBE

© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

AHDB Print Edition

AHDB Weekly e‑Newsletter

I have reviewed and consent to the terms of AHDB's Privacy Policy, and AHDB has my permission to retain my information in its database, and to forward pertinent communications to me.